Evolution of cervical cancer screening and prevention in united states and canada: Implications for public health practitioners and clinicians

Preventive Medicine

Volumn 57, Issue 5, 2013, Pages 426-433

  Saraiya, M ^a   Steben, M ^b,c   Watson, M ^a   Markowitz, L ^d  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HPV; North America; Screening; US and Canada; Vaccination

Indexed keywords

ARTICLE; CANADA; CANCER CYTODIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; DIAGNOSTIC TEST; GROUPS BY AGE; HEALTH CARE PLANNING; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; PAPANICOLAOU TEST; PHYSICIAN; PRIMARY PREVENTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION;

HPV; NORTH AMERICA; SCREENING; US AND CANADA; VACCINATION;

ADULT; CANADA; CROSS-CULTURAL COMPARISON; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH PRACTICE; SURVIVAL RATE; UNITED STATES; UTERINE CERVICAL NEOPLASMS; UTILIZATION REVIEW; VAGINAL SMEARS;

EID: 84885852668     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2013.01.020     Document Type: Article

References (70)

1. ACOG ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening. Obstet. Gynecol. 2003, 102:417-427.
2. Albrow R., Kitchener H., Gupta N., Desai M. Cervical screening in England: the past, present, and future. Cancer Cytopathol. 2012, 120:87-96.
3. American College of Obstetricians and Gynecologists ACOG Practice Bulletin: Cervical Cytology Screening 2009, No. 109:1409-1420.
4. Brouwers M.C., De Vito C., Bahirathan L., et al. Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: an implementation guideline. Implement. Sci. 2011, 6:112.
5. Brouwers M.C., De Vito C., Bahirathan L., et al. What implementation interventions increase cancer screening rates? A systematic review. Implement. Sci. 2011, 6:111.
6. Canadian Cancer Society's Steering Committee on Cancer Statistics Canadian cancer statistics 2012, Ontario, Canada 2012.
7. Canadian Task Force on Preventive Health Care Recommendations on screening for cervical cancer. CMAJ 2013, 185:35-45.
8. Castle P.E., Solomon D., Saslow D., Schiffman M. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 2008, 113:3031-3035.
9. Centers for Disease Control and Prevention FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 2010, 59:630-632.
10. Centers for Disease Control and Prevention Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb. Mortal. Wkly Rep. 2011, 60:1705-1708.
11. Centers for Disease Control and Prevention Ten great public health achievements-United States, 2001-2010. MMWR Morb. Mortal. Wkly Rep. 2011, 60:619-623.
12. Centers for Disease Control and Prevention Cancer screening - United States, 2010. MMWR Morb. Mortal. Wkly Rep. 2012, 61:41-45.
13. Centers for Disease Control and Prevention National and state vaccination coverage among adolescents aged 13-17years - United States, 2011. MMWR Morb. Mortal. Wkly Rep. 2012, 61:671-677.
14. Centers for Disease Control Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 2010, 59:626-629.
15. Centers for Disease Control and Prevention, Vaccine For Children. http://www.cdc.gov/vaccines/programs/vfc/about/index.html.
16. Cerigo H., Coutlee F., Franco E.L., Brassard P. Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. J. Med. Screen. 2012, 19:42-48.
17. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
18. Chesson H.W., Ekwueme D.U., Saraiya M., Watson M., Lowy D.R., Markowitz L.E. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012, 30:6016-6019.
19. Community Preventive Services Task Force Updated recommendations for client- and provider-oriented interventions to increase breast, cervical, and colorectal cancer screening. Am. J. Prev. Med. 2012, 43:92-96.
20. Dorell C.G., Yankey D., Santibanez T.A., Markowitz L.E. Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics 2011, 128:830-839.
21. Freeman H.P., Wingrove B.K. Excess Cervical Cancer Mortality: a Marker for Low Access to Health Care in Poor Communities 2005, National Cancer Institue, Center to Reduce Cancer Health Disparities, Rockville, MD.
22. Goldhaber-Fiebert J.D., Stout N.K., Ortendahl J., Kuntz K.M., Goldie S.J., Salomon J.A. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul. Health Metrics 2007, 5:11.
23. GSK G.S.K. (p. GSK Product Monograph for Cervarix). http://ttp://www.gsk.ca/english/docs-pdf/product-monographs/Cervarix.pdf.
24. Habbema D., De Kok I.M., Brown M.L. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 2012, 90:5-37.
25. Hogarth S., Hopkins M.M., Rodriguez V. A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA. Sociol. Health Illn. 2012, 34:234-250.
26. Horner M.J., Altekruse S.F., Zou Z., Wideroff L., Katki H.A., Stinchcomb D.G. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol. Biomarkers Prev. 2011, 20:591-599.
27. HPV Consensus Guidelines Committee Summary recommendations: Canadian consensus guidelines on human papillomavirus. J. Obstet. Gynaecol. Can. 2007, 29:S5.
28. Institute of Medicine Clinical Preventive Services for Women: Closing the Gaps, Washington, DC 2011.
29. Johnson K., Canadian Task Force on the Periodic Health Examination Periodic Health Examination, 1995 update: 1. Screening for human papillomavirus infection in asymptomatic women. Can. Med. Assoc. J. 1995, 152:483-493.
30. Lee J.W., Berkowitz Z., Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet. Gynecol. 2011, 118:4-13.
31. Malila N., Leinonen M., Kotaniemi-Talonen L., Laurila P., Tarkkanen J., Hakama M. The HPV Test has Similar Sensitivity but more Overdiagnosis than the Pap test - a Randomised Health Services Study on Cervical Cancer Screening in Finland. Int. J. Cancer 2013, 132(9):2141-2147. (May 1).
32. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007, 56:1-24.
33. Meijer C. Changing the Primary Screening Tool of the Netherlands Program: Why and How? HPV Today 2011, 2. BYPASS EDICIONES, Brussels, Belgium.
34. Merck Canada Inc. Gardasil Product Monograph 2012.
35. Moyer V.A., U.S. Preventive Services Task Force Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med 2012, 156(12):880-891. (Jun 19).
36. Murphy J., Kennedy E.B., Dunn S., et al. Cervical screening: a guideline for clinical practice in Ontario. J. Obstet. Gynaecol. Can. 2012, 34:453-458.
37. Murphy J., Kennedy E.B., Dunn S., et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J. Obstet. Gynaecol. Can. 2012, 34:443-452.
38. National Advisory Committee on Immunization (NACI) Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 2007, 33:1-31. Accessed 23rd of September 2012 at.
39. National Advisory Committee on Immunization (NACI) Update on human papillomavirus (HPV) vaccines. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 2012, 38:1-31.
40. Naus M., Ogilvie G. Human papillomavirus vaccine program in BC: a good start with room for improvement. BCMJ 2010, 52:95.
41. Niemenen, P., 2012. Optimizing Cervical Cancer Screening in Finland, HPV Today, Sept 2012 ed. BYPASS EDICIONES, Belgium, pp. 2.
42. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993, 12:186-192.
43. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011, 365(17):1576-1585. (Oct 27).
44. Phelan D.F., Boitnott J.K., Clark D.P., et al. Trends of human papillomavirus testing in cervical cancer screening at a large academic cytology laboratory. Obstet. Gynecol. 2011, 118(2 Pt 1):289-295. (PubMed PMID: 21775844, Aug). 10.1097/AOG.0b013e3182253c33.
45. Provencher DM M.K. The role of HPV testing. In: Canadian consensus guidelines on human papillomavirus. J. Obstet. Gynaecol. Can. 2007, 29:s15-s21.
46. Public Health Agency of Canada Cervical Cancer Facts and Figures 2012.
47. Rodriguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst. 2008, 100:513-517.
48. Roland K.B., Soman A., Benard V.B., Saraiya M. Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States. Am. J. Obstet. Gynecol. 2011, 205(447):e441-e448.
49. Ronco G., Biggeri A., Confortini M., et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol. Prev. 2012, 36:e1-e72.
50. Sabatino S.A., Lawrence B., Elder R., et al. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services Updated recommendations for client- and provider-oriented interventions to increase breast, cervical, and colorectal cancer screening. Am. J. Prev. Med. 2012, 43:97-118.
51. Saraiya M., Berkowitz Z., Yabroff K.R., Wideroff L., Kobrin S., Benard V. Human papillomavirus co-testing: what screening intervals are physicians recommending. Arch. Intern. Med. 2010, 170(11):977-985. (Jun 14).
52. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J. Low. Genit. Tract Dis. 2012, 16:175-204.
53. Scarinci I.C., Garcia F.A., Kobetz E., et al. Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116:2531-2542.
54. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 2011, 103:368-383.
55. Screening Performance Indicators Working Group, Cervical Cancer Prevention and Control Network Executive summary-performance monitoring for cervical cancer screening programs in Canada. Chronic Dis. Can. 2010, 31:45.
56. Smith J.C., Snider D.E., Pickering L.K., Advisory Committee on Immunization, P. Immunization policy development in the United States: the role of the Advisory Committee on Immunization Practices. Ann. Intern. Med. 2009, 150:45-49.
57. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 2001, 93:293-299.
58. Spence A.R., Goggin P., Franco E.L. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev. Med. 2007, 45:93-106.
59. Stewart D.E., Gagliardi A., Johnston M., et al. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J. Obstet. Gynaecol. Can. 2007, 29:817-828.
60. Stormo A.R., Hawkins N.A., Cooper C.P., Saraiya M. The pelvic examination as a screening tool: practices of US physicians. Arch. Intern. Med. 2011, 171:2053-2054.
61. Stormo A.R., Cooper C.P., Hawkins N.A., Saraiya M. Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. Prev. Med. 2012, 54:415-421.
62. Stuart G., Taylor G., Bancej C., et al. Report of the 2003 Pan-Canadian forum on cervical cancer prevention and control. Obstet. Gynaecol. Can. 2004, 26:1004-1014.
63. Suh C.A., Saville A., Daley M.F., et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics 2012, 129:e1437-e1445.
64. Tatsas A.D., Phelan D.F., Gravitt P.E., Boitnott J.K., Clark D.P. Practice patterns in cervical cancer screening and human papillomavirus testing. Am. J. Clin. Pathol. 2012, 138:223-229.
65. U.S. Cancer Statistics Working Group United States Cancer Statistics 1999-2008 Incidence and Mortality Web-based Report 2010, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta.
66. Vasilevska M., Ross S.A., Gesink D., Fisman D.N. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J. Public Health Policy 2012, 33:148-164.
67. Weinstock H., Berman S., Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect. Sex. Reprod. Health 2004, 36:6-10.
68. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G., Castle P.E. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J. Natl. Cancer Inst. 2009, 101:475-487.
69. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
70. zur Hausen H., Gissmann L., Steiner W., Dippold W., Dreger I. Human papilloma viruses and cancer. Bibl. Haematol. 1975, 569-571.